United States Breast Biopsy Devices Market valuation $3.77 billion by 2033 - Exclusive Report by DatamIntelligence

"The Global Breast Biopsy Devices Market reached US$ 2.25 billion in 2024 and is expected to reach US$ 3.77 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/breast-biopsy-devices-market?sp

United States: Recent Industry Developments

✅ In October 2025, Hologic launched a next-generation breast biopsy device with advanced imaging guidance and vacuum-assisted sampling. It improves diagnostic accuracy and reduces procedure time. The system targets minimally invasive breast cancer diagnostics.

✅ In September 2025, BD (Becton Dickinson) introduced a compact core needle biopsy device with integrated safety features. The device enhances precision and patient comfort. It is designed for outpatient and clinical breast tissue sampling.

✅ In August 2025, Devicor Medical Products released an automated breast biopsy system with AI-assisted lesion targeting. The system increases sampling accuracy and efficiency. It supports clinicians in early breast cancer detection.

✅ In July 2025, Siemens Healthineers launched an MRI-guided breast biopsy device for high-risk patients. The system provides real-time imaging and precise tissue sampling. It improves workflow and diagnostic confidence in breast care centers.

Japan: Recent Industry Developments

✅ In October 2025, Olympus Japan launched a minimally invasive breast biopsy device with ultrasound-guided precision. The system enhances sampling accuracy and patient safety. It is targeted for hospital and clinic use.

✅ In September 2025, Canon Medical Systems introduced a core needle breast biopsy device integrated with high-resolution imaging. The technology ensures precise lesion targeting. It supports early detection and accurate diagnosis of breast cancer.

✅ In August 2025, Terumo Japan deployed a vacuum-assisted breast biopsy device with improved ergonomics for clinical use. The device enhances procedural efficiency and patient comfort. It is suitable for outpatient and hospital settings.

✅ In July 2025, Hitachi Healthcare launched an AI-enabled breast biopsy system combining imaging and automated sampling. The system improves tissue targeting accuracy. It aids clinicians in early and reliable breast cancer diagnosis.

Breast Biopsy Devices Market: Drivers

The breast biopsy devices market is experiencing steady growth driven by increasing prevalence of breast cancer and rising awareness of early detection and diagnosis. These devices, including core needle, vacuum-assisted, and fine-needle aspiration systems, enable minimally invasive tissue sampling, providing accurate diagnostic results while reducing patient discomfort and recovery time. Growing adoption of routine breast screening programs, mammography, and diagnostic imaging is fueling demand for advanced biopsy technologies. Additionally, increasing awareness among women about breast health, preventive care, and early intervention is encouraging utilization. Expansion of hospitals, diagnostic centers, and oncology clinics, along with supportive government initiatives, is further enhancing market growth.

Technological advancements in imaging-guided biopsy devices, including ultrasound, MRI, and stereotactic systems, are improving accuracy, precision, and procedural efficiency. Collaborations between device manufacturers, research institutions, and healthcare providers are driving innovation and development of minimally invasive and patient-friendly solutions. Increasing integration of digital health tools, real-time imaging, and AI-assisted analysis is enhancing diagnostic outcomes and workflow efficiency. Awareness campaigns emphasizing early detection and the importance of routine screenings are boosting adoption rates. With continuous technological innovation and growing focus on breast cancer management, the breast biopsy devices market is poised for sustained global expansion.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/breast-biopsy-devices-market?sp

Breast Biopsy Devices Market: Major Players

STERYLAB S.r.l., Argon Medical Devices, Danaher Corporation, Cigna, Siemens Healthcare Private Limited, BD, Hologic, Inc., Devicor Medical Products, Inc., F. Hoffmann-La Roche Ltd and Cook.

Segment Covered in the Breast Biopsy Devices Market:

By Product:
Includes biopsy needles, tables, wires, and guidance systems. Biopsy needles dominate due to frequent usage in both diagnostic and screening procedures. Technological advancements enhance precision and reduce patient discomfort.

By Technique Type:
Comprises fine needle aspiration, core needle, MRI-guided core needle, and surgical biopsy. Core needle biopsy leads for its accuracy and minimal invasiveness. MRI-guided methods gain traction in detecting early-stage tumors.

By Guidance Technology:
Includes ultrasound-guided, mammography-guided, MRI-guided, and CT-guided biopsies. Ultrasound-guided systems dominate for their accuracy and cost-effectiveness. MRI and CT-guided techniques are expanding in complex case detection.

By End User:
Covers hospitals, diagnostic centers, and others. Hospitals remain major users due to advanced imaging and biopsy facilities. Diagnostic centers witness growth from early detection programs and outpatient care expansion.

Regional Analysis

North America:
Leads the market due to strong healthcare infrastructure and high breast cancer screening rates. The U.S. dominates with increased adoption of image-guided biopsies. Supportive insurance and awareness programs drive market growth.

Europe:
Shows consistent growth driven by rising cancer awareness and screening initiatives. Germany, the U.K., and France lead in adopting minimally invasive biopsy systems. Government support for early cancer detection boosts demand.

Asia-Pacific:
Fastest-growing region with increasing healthcare access and awareness. Countries like China, Japan, and India invest in advanced diagnostic technologies. Expanding private healthcare facilities accelerate adoption.

South America:
Experiences moderate growth led by Brazil and Argentina. Improving healthcare infrastructure supports adoption of modern biopsy devices. Awareness campaigns about early detection enhance regional demand.

Middle East & Africa:
Emerging region with growing focus on women's health and early diagnosis. Investments in diagnostic imaging centers support market entry. Awareness and affordability initiatives drive gradual adoption.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=breast-biopsy-devices-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.